Log In Sign up
The largest database of trusted experimental protocols

Nintedanib

Manufactured by Fujifilm
Visit Supplier
Sourced in Japan

Nintedanib is a pharmaceutical product developed by Fujifilm for use in laboratory settings. It functions as a small molecule tyrosine kinase inhibitor. The core purpose of Nintedanib is to facilitate research and experimentation in various scientific disciplines.

Automatically generated - may contain errors

Lab products found in correlation

Methylcellulose, by Fujifilm (1 mentions) Pirfenidone, by Fujifilm (1 mentions) Nintedanib, by Merck Group (1 mentions) Dimethyl sulfoxide (dmso), by Fujifilm (1 mentions) Nintedanib, by Selleck Chemicals (1 mentions) Tween 80, by Merck Group (1 mentions)

2 protocols using nintedanib

1

Pirfenidone and Nintedanib Treatment in iUIP Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
D1CC×D1BC tg mice bred on a DBA/1J background were housed in a pathogen-free animal care facility at Nagoya City University Medical School in accordance with institutional guidelines (38 (link)). iUIP mice were administered pirfenidone (3.6 mg/mouse/day, n = 8), nintedanib (1.8 mg/mouse/day, n = 10), or the vehicle (sterilized 0.5% of methylcellulose, Fujifilm-Wako, Tokyo, Japan, n = 9) orally daily from 6–14 weeks after BMS treatment.
Miura Y., Ohkubo H., Nakano A., Bourke J.E, & Kanazawa S. (2022). Pathophysiological conditions induced by SARS-CoV-2 infection reduce ACE2 expression in the lung. Frontiers in Immunology, 13, 1028613.
+ Open protocol
+ Expand
2

Nintedanib Preparation for In Vitro and In Vivo

Check if the same lab product or an alternative is used in the 5 most similar protocols
Nintedanib used in the present study was purchased from Selleck (TX, USA) and Med Chem Express (NJ, USA). Briefly, Nintedanib was dissolved in dimethyl sulfoxide (DMSO, Wako, Osaka, Japan) at a final concentration of 1–10 nM/mL for the in vitro experiments. Nintedanib was dissolved in Tween-80 (Sigma-Aldrich) solution at a final concentration of 30 mg/kg for the in vivo experiments.
Yamanaka T., Harimoto N., Yokobori T., Muranushi R., Hoshino K., Hagiwara K., Gantumur D., Handa T., Ishii N., Tsukagoshi M., Igarashi T., Tanaka H., Watanabe A., Kubo N., Araki K, & Shirabe K. (2020). Nintedanib inhibits intrahepatic cholangiocarcinoma aggressiveness via suppression of cytokines extracted from activated cancer-associated fibroblasts. British Journal of Cancer, 122(7), 986-994.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!